24/7 Wall Street
09 Jul 2026, 15:35 UTC · 2h ago
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
09 Jul 2026, 15:35 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
A leadership change at the FDA has removed a dealmaking freeze, which is expected to lead to a flood of biotech acquisitions. — Regulatory shifts that enable M&A typically trigger rapid price appreciation across a sector as companies seek acquisition premiums.
+0.80Eli Lilly completed four acquisitions in Q1 2026, funded by strong growth in its obesity and diabetes franchise. — Direct evidence of aggressive M&A by a trillion-dollar giant validates the thesis that cash-rich pharma is actively buying biotech.
+0.60Alnylam Pharmaceuticals' stock has fallen 21% YTD despite 187% revenue growth, creating a valuation dislocation that makes it a likely takeover target. — Fundamental strength paired with price weakness often attracts strategic buyers, providing a specific catalyst for the stock.
+0.40Continue reading
6 related stories
Search tags
The iShares Biotechnology ETF (IBB) has returned over 51% over the past year, signaling strong momentum in the sector. — Strong historical performance indicates a positive trend, though it may suggest the move is already partially priced in.
+0.30Which stocks this story touches
Strong financial growth in obesity and diabetes franchises and an aggressive, successful acquisition strategy.
Despite stock underperformance, the company shows massive revenue growth and is cited as a highly attractive takeover target.
Praised as a model for using tuck-in M&A to expand its franchise into new therapeutic areas.
Positive revenue growth and progress in its obesity program, benefiting from a more favorable FDA deal environment.
Mentioned as a company traders are watching closely for a potential acquisition.
Mentioned only as a historical reference for an analyst's accuracy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
